|








 |
|
Who We Are
EXT
Life Sciences, Inc. (EXT), is a biotechnology company, engaged in the
development and marketing of catalase-based compounds, designed to prevent
oxidative damage to cells and tissues. Specifically, our technologies are
designed to prevent, reduce, or eliminate the cellular accumulation of certain
highly destructive reactive oxygen species (ROS), often referred to as “free
radicals” or “oxidants”.
|
|
What We Do
EXT’s technologies arise out of published discoveries made by the company
founders, Drs. Stanley R. Terlecky and Paul A. Walton, of
Wayne State
University
School of Medicine and the
University of Western Ontario, who observed
that peroxisomes of aged cells were functionally compromised, unable to
efficiently import their constituent enzymes, especially the antioxidant enzyme catalase.
These changes led to the excessive production of hydrogen peroxide and other ROS
known to damage critical cellular components, including proteins, DNA, lipids,
and biological membranes. EXT’s strategy is to address the critical role that
catalase plays in the aging process and various degenerative diseases, where
oxidants are a factor, by genetically engineering a form of catalase that is
more efficiently imported into the peroxisome, known as Catalase-SKL. Our
goal is to utilize Catalase-SKL technologies to reduce or eliminate the
cellular production of excess hydrogen peroxide and other harmful oxidants,
thereby eliminating or reversing oxidative stress faced by humans, mammals and
other organisms.
|
|
Licensing and Collaborative Research Opportunities
EXT’s technologies have a
number of potentially beneficial applications in the medical, consumer and other
industries – wherever oxidants are known to cause damage, contribute to disease,
or accelerate the aging process. Collaborative research, development, and
licensing opportunities are available from EXT. Please contact John I. Tesija at
tesija@extlifesciences.com for additional information.
|
|
|